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Abstract trk A tyrosine kinase (the high affinity receptor for
nerve growth factor) binds to the p53 tumour suppressor protein
in vitro and in vivo. Our aim was to determine which regions of
p53 are involved in trk A association. In vitro binding
experiments using baculovirus expressed trk A and in vitro
transcribed and translated C-terminus p53 deletion mutants show
amino acids 327^338 critical for association. Also, analysis with
mutants at the N-terminus, conserved regions II, III, IV and V or
amino acid positions 173, 175, 181, 248 and 249 (which are
amino acids frequently mutated in a variety of neoplasms and
transformed cell lines), show that these sites are not involved in
trk A binding. Importantly, similar results are obtained after
immunoprecipitation of lysates from p53 negative fibroblasts
expressing trk A and the above p53 mutant proteins. These data
suggest that the amino-terminus of the oligomerisation domain of
p53 is involved in p53/trk A association. ß 2001 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
The p53 tumour suppressor phosphoprotein is characterised
by having an N-terminus transcription region, a DNA binding
domain and a C-terminus oligomerisation domain [1]. The
biochemical activity of p53 required for suppression requires
its ability to bind to DNA in a speci¢c manner and to func-
tion as a transcription factor [1^3]. Several genes are activated
by p53 and their promoters have been found to contain p53
binding sequences (reviewed in [1^4]). Interestingly, the N-
terminus region binds to several proteins (or protein com-
plexes) involved in transcription, these include TBP and
TFIID [5^7]. Although transcriptional activation represents
an important role, p53 also is able to repress transcription
from several promoters in a TATA dependent or independent
manner [8].
The C-terminus oligomerisation domain is not involved di-
rectly in DNA speci¢c recognition; however, there is evidence
showing that it contributes to the DNA binding and tran-
scriptional activity of p53 [3,9^14].
p53 is a multifunctional protein involved in apoptosis, dif-
ferentiation [15,16] and regulation of its own expression (re-
viewed in [3]). Thus, it binds to proteins, such as MDM-2,
CDC2, WT1, RPA, tms-1, the regulatory B-subunit of protein
kinase II [1,3] as well as to the high a⁄nity receptor for nerve
growth factor (NGF) trk A [16,17].
trk A is a receptor tyrosine kinase which upon NGF stim-
ulation dimerises/oligomerises, becomes phosphorylated on
tyrosine and activated to initiate a signaling cascade [18]. Ac-
tivated trk A can in turn bind and/or phosphorylate molecules
such as PLC-Q1, shc, SNT and MAP kinases [19,20] PI-3 ki-
nase does not appear to bind directly to trk A, but most likely
through shc, since mutation of the shc binding site a¡ects the
level of activation of PI-3 kinase by NGF in PC12 cells
[21,22].
Transfection of a p53 murine temperature sensitive mutant
(val-135) (ts p53) [23] into PC12 cells overexpressing trk A
[24], induces morphological changes and trk A tyrosine hyper-
phosphorylation when cells are grown at 32‡C (p53 expressed
in the wild type con¢guration), but not at 37‡C (p53 expressed
in the mutant con¢guration) in the absence of NGF stimula-
tion. Interestingly, in Saos-2 cells (an osteosarcoma cell line
devoid of trk A and p53 expression [25]) transfected with trk
A, trk A phosphorylation is not detected when expressed on
its own in cells grown at either temperature; however, phos-
phorylation is seen when co-transfected with ts p53 and cells
grown at 32‡C in the absence of NGF stimulation. To deter-
mine a possible mechanism by which p53 and trk A induce a
di¡erentiative response, association of these proteins was an-
alysed. A⁄nity puri¢ed wild type p53 and trk A associate in
vitro. Association is also detected in vivo in PC12 and
NIH3T3 cells overexpressing trk A and ts p53, PC12 and
NIH3T3 expressing trk A alone and in non-transfected
PC12 cells, indicating that overexpressed and endogenous lev-
els of trk A and p53 can bind. These experiments suggest that
p53 has a novel function which involves the stimulation of
signalling pathways possibly through the association and hy-
perphosphorylation of trk A [16].
Recently we have shown that the c-abl non-receptor tyro-
sine kinase (reviewed in [26]) is involved in p53 and trk A
binding. Endogenous c-abl can be detected when p53 and
trk A are co-precipitated. Association of p53/c-abl/trk A is
observed in NIH3T3 and PC12 cells transfected with trk A
and ts p53, NIH3T3 and PC12 cells transfected with trk A
alone and in untransfected PC12 cells suggesting that endog-
enous and overexpressed p53, trk A and c-abl can associate.
Importantly, binding of p53 to trk A is not detected in NGF
stimulated abl negative ¢broblasts expressing transfected trk
A and endogenous p53. Similar results are obtained when in
these cells p53 is activated and its levels increased by exposure
to Q radiation; suggesting that p53 and trk A preferentially
associate in the presence of c-abl [17]. To further our inves-
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tigation we wanted to determine which domains of p53 are
involved in trk A binding.
2. Materials and methods
2.1. Cell culture and transfection
p533/3 (obtained from mice with disrupted p53 alleles) and p533/
3 transfected with trk A (p533/3 trk A) ¢broblasts were maintained
in Dulbecco’s Modi¢ed Eagle’s medium supplemented with 10% heat
inactivated foetal bovine serum (Gibco BRL). Cultures were supple-
mented with 2 mM glutamine, 1 mM sodium pyruvate, and 100 IU/ml
penicillin/streptomycin (Gibco BRL).
p533/3 cells were co-transfected with pMextrk (a plasmid coding
for human proto-trk A) and pSV2neo using Lipofectamine as de-
scribed by the manufacturers (Gibco BRL). 1U105 cells were plated
in 10 cm plates and incubated overnight with media as described
above. The cells were washed three times with serum free medium
and DNA:Lipofectamine mix (15 Wg:30 Wl) was added to cells in
3 ml of serum free medium and left to incubate for 4 h at 37‡C,
washed and incubated for another 48 h in medium supplemented
with serum. Then colonies were selected in G418 (600 Wg/ml) at
37‡C and resistant colonies were screened for trk A expression by
immunoprecipitation with anti-trk A B-3 antibodies (Santa Cruz Bio-
technology). p533/3 trk A cells were maintained in 10 mg/ml G418
and passaged at 70^80% con£uency.
For transient transfections 1U108 p533/3 or p533/3 trk A cells
were mixed with 20 Wg of each p53 mutant (amount previously ti-
trated to express similar amounts of protein) and subjected to electro-
poration. Cells were grown at 37‡C for 48 h and subjected to lysis.
Sf9 cells were grown in Grace’s medium supplemented with 10%
foetal calf serum. 107 cells were infected with baculovirus expressing
proto-trk A at a multiplicity of 10 and cells were lysed 48 h post-
infection.
2.2. p53 mutants
These include deletion mutants in conserved regions I^V (p53vI 13^
19, p53vII 117^142, p53vIII 171^181, p53vIV 234^258 and p53vV
270^286) [27], three N-terminal mutants p53Nv 18 (Midgley and
Lane, personal communication), p53v 28^40 and p53v 41^49 (p53v
28^40 and p53v 41^49 were made as described in [27]), six C-terminus
mutants p53v 370, p53Cv 30, p53v 347, p53v 338, p53v 327 and
p53v 291 [28^30] and a series of point mutants (p53 173L; p53
175H; p53 175P; p53 181L; p53 248W and p53 249S) [31].
p53 mutants cloned into pGEM4Z and pGEM3Z were used for in
vitro transcription and translation. Mutants cloned into pJ36, pJ46,
pCMV and pCDNA 3.1 (Invitrogen) were used for eukaryotic expres-
sion after transfection. The EcoRI/BamHI fragment from p53v 28^40
or p53v 41^49 and the XbaI/HindIII fragment from Nv 18 were sub-
cloned into pCDNA 3.1 using standard techniques.
2.3. Immunoprecipitation and Western blotting
For in vitro experiments SF9 cells were lysed in ice cold 20 mM
Tris^HCl pH 8, 137 mM NaCl, 10% glycerol, 1 mM phenylmethyl-
sulfonyl £uoride, 0.15 U/ml aprotinin, 20 WM leupeptin, 1 mM
Na3VO4 and 1% NP-40 (lysis bu¡er). Lysates with similar protein
concentration were incubated with rabbit anti-trk 203 antibodies for
1 h at 4‡C, precipitates were collected with 30 Wl of protein G Sephar-
ose for 1 h 30 min at 4‡C and washed three times with ice cold lysis
bu¡er. These were incubated further with equal amounts of in vitro
transcribed/translated p53 mutants using the TNT T7 or SP6 Quick
coupled transcription translation System (following manufacturer’s
instructions; Promega) for 1 h at 4‡C and washed three times with
lysis bu¡er. The pellets were boiled for 2 min in sample bu¡er con-
taining 10% glycerol, 2% sodium dodecyl sulphate (SDS), 0.1 mM
dithiothreitol and 0.001% bromophenol blue. Samples were run on
7.5% SDS polyacrylamide gels. The resolved proteins were transferred
onto nitrocellulose. The blot was blocked for 1 h in 137 mM NaCl
and 20 mM Tris^HCl pH 8 (TBS) containing 2% bovine serum albu-
min (BSA); incubated with sheep anti-p53 polyclonal antibodies at
4‡C overnight and washed three times with TBS containing 0.2%
Tween 20 (TBS-T) for 5 min at room temperature. Bound antibody
was detected by incubating with peroxidase conjugated donkey anti-
sheep antibodies (diluted 1:20 000 in TBS-T) for 1 h at room temper-
ature, washed three times with TBS-T and visualised by chemolumi-
nescence (ECL Amersham).
Blots were stripped of antibody by incubating with 2% SDS, 100
mM 2-mercaptoethanol, 62.5 mM Tris^HCl pH 6.8 for 1 h at 70‡C,
rinsed three times for 15 min at room temperature with TBS and then
probed again with anti-trk 203 antibodies and developed using horse
radish peroxidase conjugated swine anti-rabbit antibodies.
For in vivo experiments cells were treated for 5 min with 100 ng/ml
NGF when indicated, then were rinsed three times with ice cold TBS
and lysed in 100 Wl of ice cold lysis bu¡er. The protein concentration
was determined using the BioRad protein assay. Lysates were immu-
noprecipitated with DO-1, PAb 421 or anti-trk A 203 antibodies for
2 h at 4‡C, precipitates were collected with 35 Wl of Protein G
Sepharose for 1 h at 4‡C and washed three times with ice cold lysis
bu¡er. Pellets were boiled in sample bu¡er. Samples were resolved on
7.5% SDS^polyacrylamide gels and the proteins transferred onto ni-
trocellulose. Blots were incubated with sheep anti-p53 or anti-trk 203,
diluted in TBS-T, overnight at 4‡C and then washed. Bound antibody
was detected by incubation with peroxidase-conjugated anti-sheep or
anti-rabbit antibodies (Dako) at a dilution of 1:20 000 in TBS-T, for
1 h at room temperature and followed by three washes with TBS-T.
Proteins were visualised by using enhanced chemiluminescence (ECL
Amersham).
3. Results and discussion
3.1. In vitro analysis of p53 and trk A association
Human p53 mutants used in this study have been described
previously [27^31]. These include deletion mutants in con-
served regions I^V (p53vI 13^19, p53vII 117^142, p53vIII
171^181, p53 vIV 234^258 and p53vV 270^286); three N-
terminal mutants with deletions in the transactivation region
Fig. 1. p53 protein diagram showing the evolutionally conserved regions I^V, the sites for phosphorylation by CDC2 and CKII, as well as the
transactivation region, DNA and MDM-2 binding domains. Deletion mutants at the N-terminus, C-terminus and conserved regions are shown
below and point mutants are shown above.
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Fig. 2. In vitro association of (A) p53 conserved region deletion mutants II^V; (B) p53 point mutants 173L, 175P, 175H, 181L, 248W and
249S; (C) p53 N-terminus deletion mutants; (D) p53 C-terminus deletion mutants with trk A. (1) Similar amounts of transcribed/translated
p53 mutants were incubated with immunoprecipitated trk A. Complexes were subjected to immunoblotting and the presence of p53 probed
with sheep anti-p53 antibodies. Each lane shows binding of mixtures containing similar amounts of trk A and each p53 mutant protein.
(2) Stripped blot probed with rabbit anti-trk 203 antibodies to show the presence of trk A. (3) Panel of in vitro transcribed/translated p53 mu-
tant proteins prior to immunoprecipitation showing similar levels of expression used in this study. (4) p53 proteins immunoprecipitated with
rabbit anti-trk 203 antibodies to detect non-speci¢c binding. Blots probed for the presence of p53 with sheep anti-p53 antibodies. This is a rep-
resentative of several experiments.
FEBS 24856 14-5-01
C. Browes et al./FEBS Letters 497 (2001) 20^2522
from which amino acids 1^43 (p53 Nv 18) (Midgley and
Lane, personal communication), 28^40 (p53v 28^40) and
41^49 (p53v 41^49) have been removed (p53v 28^40 and
p53v 41^49 were made as described in [27]); six termination
C-terminus mutants from which amino acids 370^393 (p53v
370), 363^393 (p53Cv 30), 347^393 (p53v 347), 338^393
(p53v 338), 327^393 (p53v 327) and 291^393 (p53v 291)
have been deleted and a series of point mutants previously
identi¢ed in anogenital neoplasms and transformed cell lines
(p53 173L; p53 175H; p53 175P; p53 181L; p53 248W and
p53 249S) (Fig. 1).
Initially the ability of p53 mutant proteins to associate
with trk A was assayed by in vitro binding experiments.
Cell extracts of Sf9 cells infected with baculovirus expressing
human proto-trk A [32] were immunoprecipitated with anti-
trk 203 antibodies which recognise the last 15 amino acids
of trk A [33]. Fig. 2(A2^D2) show similar amounts of trk
A in all experiments (in agreement with results obtained
by other laboratories, baculovirus expressed trk A can be
seen as a single fast migrating band [32]). Then, the immuno-
precipitates were incubated with similar amounts of in vitro
transcribed and translated wild type or mutant p53 (Fig. 2,
A3 to D3) and washed extensively. Bound proteins were an-
alysed by Western blotting; the presence of p53 was deter-
mined by incubating with sheep anti-p53 antibodies and the
presence of trk A was detected with rabbit anti-trk 203 anti-
bodies.
Fig. 2, A1 shows that wild type and deleted p53 at con-
served regions II^V can co-precipitate with trk A. Also, all
p53 point mutants tested bind to immunoprecipitated trk A
but with di¡erent abilities (Fig. 2, B1). Importantly, these
mutant proteins are not immunoprecipitated by rabbit anti-
trk 203 antibodies as shown by immunoblotting with sheep
anti-p53 antibodies (Fig. 2, A4 and B4). Binding is also de-
tected when two C-terminal phosphorylation mutants with
point substitutions at serine residues phosphorylated by
CDC2 (p53Ala 315) and CKII (p53 Ala 392) are used (data
not shown). These results suggest that conserved regions II^V
and point mutants located in the DNA binding domain are
not involved in p53/trk A association.
Binding experiments of trk A and the p53 N-terminal p53v
28^40, p53v 41^49, p53Nv 18 and p53v I mutant proteins
show all mutants able to co-precipitate with trk A. However,
when compared to wild type p53, they have reduced binding
ability only detected in long exposures (Fig. 2, C1). Immuno-
precipitation of in vitro transcribed and translated proteins
with anti-trk 203 antibodies followed by immunoblotting
with sheep anti-p53 antibodies shows low levels of cross-reac-
tivity with p53Nv 18 (a truncation of the ¢rst 43 amino acids),
similar to those detected by co-precipitation (Fig. 2, C4);
suggesting that in vitro binding between this mutant and trk
A probably does not take place.
During experiments with the p53 C-terminal deleted pro-
teins it can be seen that trk A binds to p53Cv 30, p53v 370,
p53v 347 and p53v 338, but does not appear to associate with
the extensive deletions p53v 327 and p53v 291 (Fig. 2, D1).
Also, anti-trk 203 antibodies do not immunoprecipitate these
proteins as shown by immunoblotting with sheep anti-p53
antibodies (Fig. 2, D4). This result suggests that a possible
binding site is located between amino acids 327 and 338 which
corresponds to the amino terminus of the oligomerisation
domain of p53.
3.2. In vivo analysis of p53 and trk A association
p53 negative ¢broblasts (obtained from mice with disrupted
p53 alleles) transfected with human proto-trk A (p533/3 trk
A) were transiently transfected with the N-terminus (p53v 28^
40, p53v 41^49 and p53Nv 18) and conserved region I (p53v
I) deletion mutants. Similar amounts of cell lysates were im-
munoprecipitated with rabbit anti-trk 203 antibodies and
bound proteins analysed by immunoblotting with sheep
anti-p53 antibodies. Fig. 3a shows these mutants able to co-
precipitate with trk A; however, p53v 28^40 and p53v 41^49
are more easily detected after long exposures. Similar amounts
of transiently expressed mutant proteins used for co-precipi-
tation can be detected in lysates of p533/3 trk A cells im-
munoprecipitated with PAb 421 (a monoclonal antibody that
recognises p53 at amino acids 370^378 [34]) followed by im-
munoblotting with sheep anti-p53 antibodies (Fig. 3c). The
presence of the slow and fast migrating forms of trk A can
Fig. 3. In vivo association of p53 N-terminus mutants and trk A. a:
Similar amounts of lysates of p533/3 trk A cells transiently trans-
fected with wild type p53, p53v 41^49, p53v I, p53v 28^40 and
p53Nv 18 and stimulated with NGF were immunoprecipitated with
anti-trk A 203 and the presence of p53 was determined by immuno-
blotting with sheep anti-p53 antibodies. b: Stripped blot incubated
with rabbit anti-trk 203 antibodies to show similar amounts of trk
A. c: Similar amounts of lysates of p533/3 trk A cells transiently
transfected with wild type p53, p53v 41^49, p53v I, p53v 28^40
and p53Nv 18 and stimulated with NGF were immunoprecipitated
with PAb 421 antibodies. The presence of similar amounts of p53
was determined by immunoblotting with sheep anti-p53 antibodies.
d: Similar amounts of lysates of p533/3 cells transiently transfected
with wild type p53, p53v 41^49, p53v I, p53v 28^40 and p53Nv 18
were immunoprecipitated with anti-trk 203 antibodies and the pres-
ence of p53 was determined by immunoblotting with sheep anti-p53
antibodies. For these experiments similar amounts of p53 mutants
transiently expressed in p533/3 trk A or p533/3 cells was used.
This is a representative of several experiments.
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be observed after incubation with anti-trk 203 antibodies (Fig.
3b). Immunoprecipitation with anti-trk 203 antibodies of cell
lysates from p533/3 cells transiently expressing these mutant
proteins followed by immunoblotting with sheep anti-p53
antibodies shows a very low level cross-reactivity detected
only with p53Nv 18 (Fig. 3d). However, when comparing
Fig. 3b,d it can be seen that the level of co-precipitated
p53Nv 18 is higher than the non-speci¢cally recognised by
anti-trk 203 suggesting that, in vivo, this mutant protein binds
to trk A.
Immunoprecipitation of p533/3 trk A cell lysates transi-
ently expressing the C-terminus mutant proteins with anti-trk
203 antibodies, followed by immunoblotting with sheep anti-
p53 antibodies, shows trk A binding to p53Cv 30, p53v 370,
p53v 347, p53v 338. Importantly, trk A does not appear to
associate with p53v 291 and p53v 327 (Fig. 4a). Immunopre-
cipitation of these lysates with anti-p53 DO-1 antibodies (a
monoclonal antibody that recognises amino acids 20^25 of
human p53 [35]) followed by immunoblotting with sheep
anti-p53 antibodies shows similar amounts of mutant proteins
used for co-precipitation experiments (Fig. 4c). The presence
of similar amounts of trk A can be detected after incubation
with anti-trk 203 antibodies (Fig. 4b). Immunoprecipitation,
with anti-trk 203 antibodies, of lysates from p533/3 cells
transiently expressing the C-terminus mutants followed by
immunoblotting with sheep anti-p53 antibodies, shows that
anti-trk 203 antibodies do not recognise these truncated pro-
teins (Fig. 4d).
In agreement with the in vitro ¢ndings, experiments with
p533/3 trk A cells transiently co-transfected with the con-
served region and point mutants show trk A association with
all mutant proteins. Also, p53 173L, p53 175P, p53 181L, p53
248W appear to bind to trk A with di¡erent abilities (data not
shown).
Overall, data obtained in vivo suggest that p53/trk A bind-
ing most likely involves amino acids 327^338 from the amino
terminus of the oligomerisation domain of p53.
Results obtained from in vitro binding experiments suggest
that amino acids 327^338 of p53 are involved in p53 and trk
A association. Co-precipitation experiments with the N-termi-
nus deletion mutants demonstrate that these proteins bind to
trk A with low ability. Anti-trk A 203 antibodies appear to
non-speci¢cally recognise the product of p53Nv 18 suggesting
that association between this mutant and trk A does not take
place.
In vitro results with the conserved region mutants show
that these truncated proteins can bind to trk A. Similarly,
all point mutants associate with trk A with a range of abilities
(p53 175H, p53 181L, p53 248W and p53 249S); suggesting
that these sites are not involved in p53 and trk A binding.
Unfortunately, results for the association between trk A and
p53 173L or p53 175P are not conclusive owing to co-migra-
tion of these proteins with the heavy chain of the immuno-
precipitating antibody (Fig. 2, B1).
The overall consensus is that in vitro transcribed and trans-
lated p53 proteins have ‘sticky’ properties [36]. Therefore, in
vitro results were analysed further by carrying out in vivo
experiments. Immunoprecipitations of cell lysates from
p533/3 trk A cells, expressing conserved regions II^V or
point mutants, with anti-trk A 203 antibodies followed by
immunoblotting with sheep anti-p53 antibodies show all
able to bind to trk A (data not shown). Thus, suggesting
that these sites are not involved in p53/trk A association.
These results agree with those obtained in vitro.
During immunoprecipitation of cell lysates from p533/3
trk A cells, expressing the N-terminus mutants, with anti-trk
A 203 antibodies followed by immunoblotting with sheep
anti-p53 antibodies p53v 28^40, p53v 41^49, p53Nv 18 and
p53v I are able to co-precipitate with trk A, but in these
experiments, p53v 28^40 and p53v 41^49 appear to bind
with low ability.
A comparison of in vitro and in vivo results suggest that
variability in binding e⁄ciency by the N-terminus and point
mutants, when expressed in di¡erent environments, could be
due to unknown protein conformational changes acquired as
a result of the mutation, rather than to the absence of a site
directly involved in trk A binding.
Fig. 4. In vivo association of p53 C-terminus mutants and trk A. a:
Similar amounts of lysates of p533/3 trk A cells transiently trans-
fected with wild type p53, p53v 370, p53Cv 30, p53v 347, p53v
338, p53v 327 and p53v 291 and stimulated with NGF were immu-
noprecipitated with anti-trk A 203 and the presence of p53 was de-
termined by immunoblotting with sheep anti-p53 antibodies. b:
Stripped blot incubated with rabbit anti-trk 203 antibodies to show
similar amounts of trk A. c: Similar amounts of lysates of p533/3
trk A cells transiently transfected with wild type p53, p53v 370,
p53Cv 30, p53v 347, p53v 338, p53v 327 and p53v 291 and stimu-
lated with NGF were immunoprecipitated with DO-1 antibodies.
The presence of similar amounts of p53 was determined by immu-
noblotting with sheep anti-p53 antibodies. d: Similar amounts of ly-
sates of p533/3 cells transiently transfected with wild type p53,
p53v 370, p53Cv 30, p53v 347, p53v 338, p53v 327 and p53v 291
were immunoprecipitated with anti-trk 203 antibodies and the pres-
ence of p53 was determined by immunoblotting with sheep anti-p53
antibodies. For these experiments similar amounts of p53 mutants
transiently expressed in p533/3 trk A or p533/3 cells was used.
This is a representative of several experiments.
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Overall, results obtained with the N-terminus and point
mutant proteins indicate that these regions are most likely
not involved in p53 and trk A association.
As of results obtained in vitro, in vivo analyses display non-
speci¢c recognition of p53Nv 18 by anti-trk 203 antibodies
(observed after direct immunoprecipitation); however, the lev-
el of co-precipitated p53Nv 18 is higher than that non-specif-
ically recognised by anti-trk 203 suggesting that, in vivo,
p53Nv 18 binds to trk A; thus, amino acids 1^43 are not
involved in trk A/p53 association.
There is evidence showing that p53v I does not bind to
MDM-2 [27]. Hence, our results suggest that trk A may not
necessarily interfere with MDM-2 binding because p53v I can
associate with trk A.
In vivo analysis of trk A association with the C-terminus
mutant proteins show p53v 338, p53v 347, p53v 370 and
p53Cv 30 able to bind to the receptor; however, p53v 291
and p53v 327 do not co-precipitate with trk A, suggesting that
the binding site is located at amino acids 327^338. This result
agrees with data obtained in vitro.
p53 and c-abl can bind after genotoxic damage [37^39].
Also, recently we have shown that c-abl is required for p53
and trk A association [17]. Since p53/trk A binding is prefer-
entially detected in the presence of c-abl; association between
p53 mutants and endogenous c-abl was analysed using anti-
abl ab-3 antibodies which can co-precipitate p53/c-abl/trk A
[17]. However, when anti-abl ab-3 antibodies are used to di-
rectly immunoprecipitate wild type and p53 mutant proteins
transiently expressed in abl3/3 ¢broblasts ; immunoblotting
with anti-p53 antibodies shows that, as already published,
anti-abl ab-3 does not recognise wild type p53 but that it
can non-speci¢cally recognise several mutant proteins (data
not shown), strongly suggesting that the ‘sticky’ properties
generally attributed to mutant p53 proteins are in£uencing
these results [36].
Overall, it can be concluded that in vitro trk A/p53 associ-
ation appears to require amino acid positions 327^338 located
at the amino terminus of the oligomerisation domain of p53.
Importantly, the in vivo analysis gave similar results, provid-
ing further evidence that this site is most likely involved in
p53/trk A binding. Since our previous data show that c-abl is
required for this association, it is possible that this region is
involved in c-abl and p53 recognition. However, the latter
needs to be characterised further.
Acknowledgements: We thank David Lane and Carol Midgley for
plasmids p53 Nv 18, p53Cv 30 and sheep anti-p53 antibodies, Nicola
Marston and Karen Vousden for providing all published p53 mutants
as well as p53v 28^40 and p53v 41^49 and John Jenkins for
pB12CMV 338. We are grateful to David Kaplan and Dionisio Mar-
tin Zanca for rabbit anti-trk A 203 antibodies and to Natalie Teich
for critical reading of this manuscript.
References
[1] Ko, L.J. and Prives, C. (1996) Genes Dev. 10, 1054^1072.
[2] Hansen, R. and Oren, M. (1997) Curr. Opin. Genet. Dev. 7, 46^
51.
[3] Prives, C. and Hall, P.A. (1999) J. Pathol. 187, 112^126.
[4] Levine, A.J. (1997) Cell 88, 323^331.
[5] Ragimov, N., Krauskopf, A., Navot, N., Rotter, V., Oren, M.
and Aloni, Y. (1993) Oncogene 8, 1183^1193.
[6] Lu, H. and Levine, A.J. (1995) Proc. Natl. Acad. Sci. USA 92,
5154^5158.
[7] Thut, C.J., Chen, J.L., Klemin, R. and Tjian, R. (1995) Science
267, 100^104.
[8] Sathanam, U., Ray, A. and Seghal, P.B. (1991) Proc. Natl. Acad.
Sci. USA 88, 7605^7609.
[9] Hupp, T.R., Meek, D.W., Midgley, C.A. and Lane, D.P. (1992)
Cell 71, 875^886.
[10] Hupp, T.R., Sparks, A. and Lane, D.P. (1995) Cell 83, 237^245.
[11] Bakalkin, G., Yakoleva, T., Selinova, G., Magnusson, K.P.,
Szekely, L., Kiseleva, E., Klein, G., Terenius, L. and Wiman,
K.G. (1994) Proc. Natl. Acad. Sci. USA 91, 413^417.
[12] Bayle, J.H., Elebaas, B. and Levine, A.J. (1995) Proc. Natl.
Acad. Sci. USA 92, 5729^5733.
[13] Jarayaman, J. and Prives, C. (1995) Cell 81, 1021^1029.
[14] Molinari, M. and Milner, J. (1995) Oncogene 10, 1849^1854.
[15] Shaulsky, G., Gold¢nger, A., Peled, A. and Rotter, V. (1991)
Proc. Natl. Acad. Sci. USA 88, 8982^8986.
[16] Montano, X. (1997) Oncogene 15, 245^256.
[17] Brown, A., Browes, C., Mitchell, M. and Montano, X. (2000)
Oncogene 19, 3032^3040.
[18] Kaplan, D.R. and Stephens, R.M. (1994) J. Neurobiol. 25, 1404^
1417.
[19] Kaplan, D.R. and Miller, F.D. (1997) Curr. Opin. Cell Biol. 9,
213^221.
[20] Kaplan, D.R. and Miller, F.D. (2000) Curr. Opin. Neurobiol. 10,
381^391.
[21] Hallberg, B., Ashcroft, M., Loeb, D.M., Kaplan, D.R. and
Downward, J. (1998) Oncogene 17, 691^697.
[22] Ashcroft, M., Stephens, R.M., Hallberg, B., Downward, J. and
Kaplan, D.R. (1999) Oncogene 18, 4586^4597.
[23] Michalovitz, D., Halevy, O. and Oren, M. (1990) Cell 62, 671^
680.
[24] Hempstead, B.L., Rabin, S.J., Kaplan, L., Reid, S., Parada, L.F.
and Kaplan, D.R. (1992) Neuron 9, 883^896.
[25] Masuda, H., Miller, C., Koe¥er, H.P., Battifora, H. and Cline,
M.J. (1987) Proc. Natl. Acad. Sci. USA 84, 7716^7719.
[26] Kharbanda, S., Yuan, Z.-M., Weichselbaum, R. and Kufe, D.
(1998) Oncogene 17, 3309^3318.
[27] Marston, N.J., Crook, T. and Vousden, K.H. (1994) Oncogene 9,
2707^2716.
[28] Tarunina, M. and Jenkins, J.R. (1993) Oncogene 8, 3165^3173.
[29] Cox, L.S., Hupp, T., Midgley, C.A. and Lane, D.P. (1995)
EMBO J. 14, 2099^2105.
[30] Marston, N.J., Jenkins, J.R. and Vousden, K.H. (1995) Onco-
gene 10, 1709^1715.
[31] Crook, T., Marsten, N., Sara, A.E. and Vousden, K.H. (1994)
Cell 79, 817^827.
[32] Stephens, R.M., Loeb, D.M., Copeland, T.D., Pawson, T.,
Greene, A.L. and Kaplan, D.R. (1994) Neuron 12, 691^705.
[33] Martin Zanca, D., Hughes, S. and Barbacid, M. (1986) Nature
319, 743^748.
[34] Harlow, E., Crawford, L.V., Pim, D.C. and Williamson, N.M.
(1981) J. Virol. 39, 861^869.
[35] Lane, D.P., Stephen, C.W., Midgley, C.A., Sparks, A., Hupp,
T.R., Daniels, D.A., Greaves, R., Reid, A., Vojtesek, B. and
Picksley, S.M. (1996) Oncogene 12, 2461^2466.
[36] Prives, C. (1994) Cell 78, 543^546.
[37] Yuan, Z.-M., Huang, Y., Fan, M.-M., Sawyers, C., Kharbanda,
S. and Kufe, D. (1996) J. Biol. Chem. 271, 26457^26460.
[38] Yuan, Z.-M., Huang, Y., Whang, Y., Sawyers, C., Weichsel-
baum, R., Kharbanda, S. and Kufe, D. (1996) Nature 382,
272^274.
[39] Yuan, Z.-M., Huang, Y., Ishiko, T., Kharbanda, S., Weichsel-
baum, R. and Kufe, D. (1997) Proc. Natl. Acad. Sci. USA 94,
1437^1440.
FEBS 24856 14-5-01
C. Browes et al./FEBS Letters 497 (2001) 20^25 25
